4/n Hypersialylation of the CD52 glycopeptide determines selection and binding to the receptor through the O-glycan and binding to Siglec-10 through the N-glycan [https://doi.org/10.1016/j.jbc.2025.108350] and [https://doi.org/10.1101/2025.06.10.658867]
November 27, 2025 at 6:24 PM
4/n Hypersialylation of the CD52 glycopeptide determines selection and binding to the receptor through the O-glycan and binding to Siglec-10 through the N-glycan [https://doi.org/10.1016/j.jbc.2025.108350] and [https://doi.org/10.1101/2025.06.10.658867]
Exploring the interaction of Neu5Ac, the natural sialic acid ligand, with Siglec-10 through 100 ns of molecular dynamics.
Throughout the simulation, the salt bridge to R119 and R127 is marked, providing a stable reference system for comparing a set of modified analogs. #glycotime
Throughout the simulation, the salt bridge to R119 and R127 is marked, providing a stable reference system for comparing a set of modified analogs. #glycotime
July 18, 2026 at 11:55 PM
Exploring the interaction of Neu5Ac, the natural sialic acid ligand, with Siglec-10 through 100 ns of molecular dynamics.
Throughout the simulation, the salt bridge to R119 and R127 is marked, providing a stable reference system for comparing a set of modified analogs. #glycotime
Throughout the simulation, the salt bridge to R119 and R127 is marked, providing a stable reference system for comparing a set of modified analogs. #glycotime
When glycan recognition is linked to immune response, you need fine tuning! 😎
Here ⬇️ we show how human Siglecs act as molecular precision tools, recognising the glycan and also the biological environment (or context) these glycans are found in. A 1/5 #glycotime🧵 ⬇️
doi.org/10.1101/2025...
Here ⬇️ we show how human Siglecs act as molecular precision tools, recognising the glycan and also the biological environment (or context) these glycans are found in. A 1/5 #glycotime🧵 ⬇️
doi.org/10.1101/2025...
June 22, 2025 at 10:42 AM
When glycan recognition is linked to immune response, you need fine tuning! 😎
Here ⬇️ we show how human Siglecs act as molecular precision tools, recognising the glycan and also the biological environment (or context) these glycans are found in. A 1/5 #glycotime🧵 ⬇️
doi.org/10.1101/2025...
Here ⬇️ we show how human Siglecs act as molecular precision tools, recognising the glycan and also the biological environment (or context) these glycans are found in. A 1/5 #glycotime🧵 ⬇️
doi.org/10.1101/2025...
In our contribution, @silviadandrea.bsky.social and I looked at the binding of GT1b (Siglec-10 fav buddy), which is polysialylated and has a very fancy structure 😍 MD simulations show how *multiple Arg* contribute to the recognition and binding, providing an atomistic perspective to experiment ⬇️ 2/3
June 12, 2025 at 8:27 AM
In our contribution, @silviadandrea.bsky.social and I looked at the binding of GT1b (Siglec-10 fav buddy), which is polysialylated and has a very fancy structure 😍 MD simulations show how *multiple Arg* contribute to the recognition and binding, providing an atomistic perspective to experiment ⬇️ 2/3
New fabulous #glycotime fresh off the bioRxiv press!⬇️ 🎉 In this brilliant team effort led by Klaudia Sobczak, Jesús Jimenez-Barbero, and June Ereño Orbea 🤩 with many contributions 🌍, we characterised the 3D structure + binding mechanism of sialosides by Siglec-10 🧵 1/3
doi.org/10.1101/2025...
doi.org/10.1101/2025...
doi.org
June 12, 2025 at 8:20 AM
New fabulous #glycotime fresh off the bioRxiv press!⬇️ 🎉 In this brilliant team effort led by Klaudia Sobczak, Jesús Jimenez-Barbero, and June Ereño Orbea 🤩 with many contributions 🌍, we characterised the 3D structure + binding mechanism of sialosides by Siglec-10 🧵 1/3
doi.org/10.1101/2025...
doi.org/10.1101/2025...
RRID:AB_1724153 from @thermofishersci.bsky.social was used by authors in their Cell Reports Medicine paper. Thanks for making your methods matter! #OpenScience #RRID #STMpublishing
Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
Read the full paper: Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
doi.org
March 21, 2026 at 7:00 AM
RRID:AB_1724153 from @thermofishersci.bsky.social was used by authors in their Cell Reports Medicine paper. Thanks for making your methods matter! #OpenScience #RRID #STMpublishing
The authors included RRIDs in their in Structure paper! Thanks for making your methods matter! #BetterScience #methodsmatter #reproducibility
Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10
Read the full paper: Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10
doi.org
February 26, 2026 at 7:54 PM
The authors included RRIDs in their in Structure paper! Thanks for making your methods matter! #BetterScience #methodsmatter #reproducibility
The authors included RRIDs in their paper! RRIDs improve reproducibility in scientific research. #RRID #RRID #reproducibility
Targeting Interactions between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
doi.org
December 7, 2025 at 8:00 AM
The authors included RRIDs in their paper! RRIDs improve reproducibility in scientific research. #RRID #RRID #reproducibility
RRIDs were included in this None paper. Thanks for making your methods matter! #OpenScience #methodsmatter #STMpublishing
Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment
doi.org
August 15, 2025 at 7:01 AM
RRIDs were included in this None paper. Thanks for making your methods matter! #OpenScience #methodsmatter #STMpublishing
OncoC4 discovered the 'don't eat me' switch tumors use to hide. Now they're flipping it off.
https://yespress.io/oncoc4-inc?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/oncoc4-inc?utm_source=bluesky&utm_medium=social via Yespress
OncoC4, Inc.
The Maryland biotech that discovered the CD24-Siglec-10 checkpoint and is rewriting the rules of cancer immunotherapy.
yespress.io
July 7, 2026 at 4:02 AM
OncoC4 discovered the 'don't eat me' switch tumors use to hide. Now they're flipping it off.
https://yespress.io/oncoc4-inc?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/oncoc4-inc?utm_source=bluesky&utm_medium=social via Yespress
Stromal cell sialylation suppresses NK cell function through Siglec-10 engagement #glycotime www.biorxiv.org/content/10.1...
Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axis
The immunosuppressive tumour microenvironment (TME) reduces immune response effectiveness in stromal-rich tumours, including CMS4 colorectal cancer (CRC). Mesenchymal stromal cells (MSCs), precursors ...
www.biorxiv.org
March 27, 2025 at 4:59 PM
Stromal cell sialylation suppresses NK cell function through Siglec-10 engagement #glycotime www.biorxiv.org/content/10.1...
#authorinterview Pratima Saini, Research associate with Prof. Mohamed Abdel-Mohsen lab at Northwestern University talks about her work on "A New Siglec-10 Antibody Reignites the Immune Attack on Pancreatic Cancer" #cancer biopatrika.com/academia/res... via @biopatrika @abdelmohsenlab.bsky.social
A New Siglec-10 Antibody Reignites the Immune Attack on Pancreatic Cancer - BioPatrika
Researcher Spotlight - By exposing this hidden glyco-immune checkpoint, we open a fresh path to finally make pancreatic cancer vulnerable to immunotherapy strategies
biopatrika.com
November 25, 2025 at 7:49 AM
#authorinterview Pratima Saini, Research associate with Prof. Mohamed Abdel-Mohsen lab at Northwestern University talks about her work on "A New Siglec-10 Antibody Reignites the Immune Attack on Pancreatic Cancer" #cancer biopatrika.com/academia/res... via @biopatrika @abdelmohsenlab.bsky.social
Great work by PhD graduate Dr. Jhon Enterina and current PhD candidate Sung-Yao (Sam) Lin. Lots of help from others in the lab as well, including a fruitful collaboration with @oj-lab.bsky.social, whose lab carried out the proteomics from proximity labeling to identify Siglec-G/10 ligands on Tfh.
May 11, 2026 at 1:45 PM
Great work by PhD graduate Dr. Jhon Enterina and current PhD candidate Sung-Yao (Sam) Lin. Lots of help from others in the lab as well, including a fruitful collaboration with @oj-lab.bsky.social, whose lab carried out the proteomics from proximity labeling to identify Siglec-G/10 ligands on Tfh.
New work on the structure of Siglec-10. Great collaboration that was solidified with a visit to Spain last year with fantastic discussions with June Ereno-Orbea and Jesus Jimenez-Barbero. Nice contributions on modeling by @elisafadda.bsky.social.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
The unique molecular recognition features of Siglec-10: structural insights into sialoglycan and antibody interactions
Siglec-10 is a sialic acid-binding immunoglobulin-like lectin implicated in immune regulation, yet its molecular basis for ligand recognition and functional role in immune modulation remain poorly def...
www.biorxiv.org
June 12, 2025 at 1:26 PM
New work on the structure of Siglec-10. Great collaboration that was solidified with a visit to Spain last year with fantastic discussions with June Ereno-Orbea and Jesus Jimenez-Barbero. Nice contributions on modeling by @elisafadda.bsky.social.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
#bioGUNE_Thesis | Researcher Andrea Fernández will defend her #PhD thesis:
📖 “Synthesis and Evaluation of Glycomimetics as potential Siglec Immunomodulators”
👤 June Ereño-Orbea & Niels Reichardt @cicbiomagune.bsky.social
🔗 ow.ly/1Jnq50XzWe7
🕜 Wednesday, December 10th, 10:30H
📖 “Synthesis and Evaluation of Glycomimetics as potential Siglec Immunomodulators”
👤 June Ereño-Orbea & Niels Reichardt @cicbiomagune.bsky.social
🔗 ow.ly/1Jnq50XzWe7
🕜 Wednesday, December 10th, 10:30H
December 2, 2025 at 7:38 AM
#bioGUNE_Thesis | Researcher Andrea Fernández will defend her #PhD thesis:
📖 “Synthesis and Evaluation of Glycomimetics as potential Siglec Immunomodulators”
👤 June Ereño-Orbea & Niels Reichardt @cicbiomagune.bsky.social
🔗 ow.ly/1Jnq50XzWe7
🕜 Wednesday, December 10th, 10:30H
📖 “Synthesis and Evaluation of Glycomimetics as potential Siglec Immunomodulators”
👤 June Ereño-Orbea & Niels Reichardt @cicbiomagune.bsky.social
🔗 ow.ly/1Jnq50XzWe7
🕜 Wednesday, December 10th, 10:30H
“#Siglec−sialoglycan interactions are affected by sialic acid type (N-acetylneuraminic acid and N-glycolylneuraminic acid), 9-O-acetylation, linkage, sulfation, and carrier, are of varying affinities ( ~ 10 nM-µM/mM), and cis interactions are key regulatory features” #glycotime
An atlas of human siglecs integrates expression, affinity, and cis/trans sialoglycan recognition profiles - Nature Communications
Cells are coated with glycans that are linked to cellular recognition via sialic acid-binding immunoglobulin-like lectins (Siglecs). Here the authors present a resource characterising human Siglec exp...
www.nature.com
April 28, 2026 at 6:32 PM
“#Siglec−sialoglycan interactions are affected by sialic acid type (N-acetylneuraminic acid and N-glycolylneuraminic acid), 9-O-acetylation, linkage, sulfation, and carrier, are of varying affinities ( ~ 10 nM-µM/mM), and cis interactions are key regulatory features” #glycotime
“#HIV infection reprograms… infected cells to increase… sialoglycan ligands for Siglec-3, −7, -9 … disruption of these interactions using 10-1074-SiaD, an … antibody conjugated to sialidase… enhances… (immune) killing of HIV-infected cells…” #glycotime
www.nature.com/articles/s41...
www.nature.com/articles/s41...
HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing - Nature Communications
Immune evasion mechanisms of initial HIV infection are incompletely understood. Here, the authors show that HIV rewires the glycosylation machinery of infected myeloid cells, forming a glycan shield t...
www.nature.com
January 7, 2026 at 9:22 AM
“#HIV infection reprograms… infected cells to increase… sialoglycan ligands for Siglec-3, −7, -9 … disruption of these interactions using 10-1074-SiaD, an … antibody conjugated to sialidase… enhances… (immune) killing of HIV-infected cells…” #glycotime
www.nature.com/articles/s41...
www.nature.com/articles/s41...
“In this study, we identified integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for #Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC” #SialicAcid #Glycotime
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
AbstractTumor-associated macrophages (TAM) in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) exhibit immunosuppressive phenotypes and impaired phagocytic activity, facilitati...
aacrjournals.org
November 6, 2025 at 3:52 AM
“In this study, we identified integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for #Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC” #SialicAcid #Glycotime
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
"These findings suggest that Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore antitumor immunity."
INJECT THIS INTO YOUR VEINS
DETAILS RUN THE WORLD
CUTE STORIES ARE FOR CHUMPS
INJECT THIS INTO YOUR VEINS
DETAILS RUN THE WORLD
CUTE STORIES ARE FOR CHUMPS
February 3, 2026 at 2:44 PM
"These findings suggest that Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore antitumor immunity."
INJECT THIS INTO YOUR VEINS
DETAILS RUN THE WORLD
CUTE STORIES ARE FOR CHUMPS
INJECT THIS INTO YOUR VEINS
DETAILS RUN THE WORLD
CUTE STORIES ARE FOR CHUMPS
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction...
academic.oup.com/abt/article/...
#CD24 #Antibody
🎇🎇IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction...
academic.oup.com/abt/article/...
#CD24 #Antibody
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti...
Statement of Significance: Novel humanized mAb MM47 has excellent anti-tumor efficacy by blocking CD24/Siglec-10 interaction with strong antibody-dependent
academic.oup.com
February 21, 2026 at 12:42 AM
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction...
academic.oup.com/abt/article/...
#CD24 #Antibody
🎇🎇IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction...
academic.oup.com/abt/article/...
#CD24 #Antibody
Upon engagement with Siglec-9, antigen-presenting cells like macrophages have reduced function, and in mice, introducing this mutation into the delta spike protein (S375F) resulted in a ~10-fold drop in antibody titers. And reverting it with Omicron resulted in an ~10-fold increase in titers.
March 23, 2025 at 4:34 AM
Upon engagement with Siglec-9, antigen-presenting cells like macrophages have reduced function, and in mice, introducing this mutation into the delta spike protein (S375F) resulted in a ~10-fold drop in antibody titers. And reverting it with Omicron resulted in an ~10-fold increase in titers.
Siglec-9 is an inhibitory receptor that tones down immune responses, in this case, blocking antigen presentation by the cells of the immune system. If this mutation is reverted to the pre-Omicron version antibody responses to Omicron increased by about 10-fold. Furthermore, when the mutation was...
Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity | PNAS
Given the role of myeloid cells in T cell activation and in the antitumor response,
targeting checkpoint molecules expressed on this population rep...
www.pnas.org
February 6, 2025 at 11:29 PM
Siglec-9 is an inhibitory receptor that tones down immune responses, in this case, blocking antigen presentation by the cells of the immune system. If this mutation is reverted to the pre-Omicron version antibody responses to Omicron increased by about 10-fold. Furthermore, when the mutation was...